Non-invasive method to diagnose endometrial cancer
Non-Invasive Diagnosis of Endometrial Cancer
This study is testing a new, less painful way to diagnose endometrial cancer by looking at cervical samples to see if it works better than traditional biopsies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Paris) |
| Trial ID | NCT05737797 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of next-generation sequencing and microsatellite analysis of cervical cytology as a non-invasive alternative for diagnosing endometrial cancer. By analyzing cervical samples from patients with confirmed endometrial carcinoma, the researchers aim to identify genetic variants associated with the disease. The study focuses on the sensitivity of these methods compared to traditional invasive biopsies, which can be painful and have moderate sensitivity. It is a proof-of-concept study that could pave the way for less invasive diagnostic techniques.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with endometrial cancer who are scheduled for a hysterectomy.
Not a fit: Patients currently undergoing chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive and more comfortable diagnostic option for patients suspected of having endometrial cancer.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in utilizing non-invasive methods for cancer diagnosis, but this specific application is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Endometrial cancer requiring hysterectomy * Patient covered by French social Security * Patient capable of giving written informed consent Exclusion Criteria: - Chemotherapy
Where this trial is running
Paris
- Medical genetics department — Paris, France (Recruiting)
Study contacts
- Study coordinator: Patrick BENUSIGLIO, MD PhD
- Email: patrick.benusiglio@aphp.fr
- Phone: + 33 1 42 17 76 59
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.